×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
NASDAQ:STIM

Neuronetics Stock Forecast, Price & News

$3.34
+0.16 (+5.03%)
(As of 07/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$3.11
$3.35
50-Day Range
$2.09
$3.71
52-Week Range
$1.98
$15.50
Volume
2,738 shs
Average Volume
300,325 shs
Market Capitalization
$88.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Neuronetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
215.3% Upside
$10.50 Price Target
Short Interest
Bearish
5.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$794,795 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.71) to ($1.40) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.71 out of 5 stars

Medical Sector

560th out of 1,428 stocks

Surgical & Medical Instruments Industry

67th out of 138 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

Neuronetics logo

About Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

STIM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STIM
Employees
175
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/05/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+214.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.5
Research Coverage
4 Analysts

Profitability

Net Income
$-31,190,000.00
Pretax Margin
-59.70%

Debt

Sales & Book Value

Annual Sales
$55.31 million
Book Value
$3.23 per share

Miscellaneous

Free Float
25,243,000
Market Cap
$88.94 million
Optionable
Not Optionable
Beta
2.01














Neuronetics Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Neuronetics stock.
View analyst ratings for Neuronetics
or view top-rated stocks.

What is Neuronetics' stock price forecast for 2022?

4 Wall Street research analysts have issued 1 year price targets for Neuronetics' stock. Their STIM stock forecasts range from $9.00 to $12.00. On average, they predict Neuronetics' stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 214.4% from the stock's current price.
View analysts' price targets for Neuronetics
or view top-rated stocks among Wall Street analysts.

How has Neuronetics' stock price performed in 2022?

Neuronetics' stock was trading at $4.46 on January 1st, 2022. Since then, STIM stock has decreased by 25.1% and is now trading at $3.34.
View the best growth stocks for 2022 here
.

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Neuronetics
.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) announced its quarterly earnings data on Thursday, May, 12th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.01. Neuronetics had a negative trailing twelve-month return on equity of 39.03% and a negative net margin of 59.70%. During the same period in the prior year, the company posted ($0.31) earnings per share.
View Neuronetics' earnings history
.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics issued an update on its second quarter 2022 earnings guidance on Thursday, June, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $15.00 million-$16.00 million, compared to the consensus revenue estimate of $15.28 million.

Who are Neuronetics' key executives?

Neuronetics' management team includes the following people:
  • Mr. Keith J. Sullivan, Pres, CEO & Director (Age 64, Pay $1.25M) (LinkedIn Profile)
  • Mr. Stephen J. Furlong M.S., Sr. VP, CFO & Treasurer (Age 57, Pay $680.02k) (LinkedIn Profile)
  • Mr. W. Andrew Macan, Sr. VP, Gen. Counsel, Chief Compliance Officer, Sec. & Member of Office of the Pres (Age 49, Pay $548.83k)
  • Ms. Sara Grubbs, VP of Sales
  • Ms. Claire Sears, VP of Marketing
  • Ms. Kara Thornton, VP of HR & Sr. Director

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $3.34.

How much money does Neuronetics make?

Neuronetics (NASDAQ:STIM) has a market capitalization of $88.94 million and generates $55.31 million in revenue each year. The company earns $-31,190,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.

How many employees does Neuronetics have?

Neuronetics employs 175 workers across the globe.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for Neuronetics is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206.

This page (NASDAQ:STIM) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.